RxDoctor Payments Data

David Hom, MD

Urology · Amery, WINPI 1659351583

Payments from drug & device makers

$1,573in general payments, 2019–2025

Across 47 payments — averaging $33.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$733
  • Johnson & Johnson$423
  • Endo Pharmaceuticals Inc.$114
  • Neotract Inc.$97
  • Antares Pharma, Inc.$63
  • Pfizer$49
  • plus $93 from 4 others

What the payments were for

  • Food & beverage$1,18976%
  • Education$38424%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,573 in reported general payments places this provider in the 60th percentile of 215 urology providers in Wisconsin.

See all urology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$65,023
Medicare patients
347
Services billed
650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide12$162,791
MyrbetriqMirabegron170$148,913
TrelstarTriptorelin Pamoate12$58,243
GemtesaVibegron41$30,843
ElmironPentosan Polysulfate Sodium11$16,305
Tamsulosin Hcl947$15,924
Finasteride745$7,803
Silodosin40$4,418
Methenamine Hippurate65$3,854
Oxybutynin Chloride ErOxybutynin Chloride181$3,056
Dutasteride74$2,434
Solifenacin Succinate49$2,387
Tolterodine Tartrate ErTolterodine Tartrate12$1,345
Alfuzosin Hcl ErAlfuzosin Hcl40$832
Doxazosin Mesylate41$678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$733$311,704182 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 215 urology providers in Wisconsin.

Other urology in Amery

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →